Quoin Pharmaceuticals Ltd DRC (QNRX) - Total Liabilities
Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) has total liabilities worth $7.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Quoin Pharmaceuticals Ltd DRC operating cash flow efficiency to assess how effectively this company generates cash.
Quoin Pharmaceuticals Ltd DRC - Total Liabilities Trend (2015–2024)
This chart illustrates how Quoin Pharmaceuticals Ltd DRC's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Quoin Pharmaceuticals Ltd DRC's assets to evaluate the company's liquid asset resilience ratio.
Quoin Pharmaceuticals Ltd DRC Competitors by Total Liabilities
The table below lists competitors of Quoin Pharmaceuticals Ltd DRC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adcore Inc
TO:ADCO
|
Canada | CA$8.23 Million |
|
SaveLend Group AB
ST:YIELD
|
Sweden | Skr266.65 Million |
|
SONOKONG Co. Ltd
KQ:066910
|
Korea | ₩70.61 Billion |
|
Tonkens Agrar AG
XETRA:GTK
|
Germany | €27.89 Million |
|
Pharmena S.A.
WAR:PHR
|
Poland | zł850.00K |
|
ERWE Immobilien AG
F:ERWE
|
Germany | €186.90 Million |
|
Marine Petroleum Trust
NASDAQ:MARPS
|
USA | $0.00 |
|
Baru Gold Corp
V:BARU
|
Canada | CA$8.91 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Quoin Pharmaceuticals Ltd DRC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Quoin Pharmaceuticals Ltd DRC stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quoin Pharmaceuticals Ltd DRC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quoin Pharmaceuticals Ltd DRC (2015–2024)
The table below shows the annual total liabilities of Quoin Pharmaceuticals Ltd DRC from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.50 Million | -0.01% |
| 2023-12-31 | $6.51 Million | -7.74% |
| 2022-12-31 | $7.05 Million | -18.95% |
| 2021-12-31 | $8.70 Million | +8.95% |
| 2020-12-31 | $7.99 Million | +325.43% |
| 2019-12-31 | $1.88 Million | +4.45% |
| 2018-12-31 | $1.80 Million | -45.85% |
| 2017-12-31 | $3.32 Million | +135.52% |
| 2016-12-31 | $1.41 Million | +91.70% |
| 2015-12-31 | $735.02K | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Net… Read more